Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adult Participants With New-Onset Generalized Myasthenia Gravis

NCT06909214 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT06909214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06909214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adult Participants With New-Onset Generalized Myasthenia Gravis
Lead sponsor
argenx
Phase
Phase 4
Overall status
Recruiting
Start date
April 17, 2025
Completion date
May 31, 2027
Enrollment
30 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

new onset generalized myasthenia gravis (gmg)